As of January 22, 2025, Regulus Therapeutics (RGLS) has a market cap of $81.220 million USD. According to our data, Regulus Therapeutics is ranked No.7846 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $81.22 M |
-21.52%
|
Dec 31, 2024 | $0.10 B |
23.44%
|
Dec 29, 2023 | $83.84 M |
-6.57%
|
Dec 30, 2022 | $89.74 M |
-57.19%
|
Dec 31, 2021 | $0.21 B |
-76.30%
|
Dec 31, 2020 | $0.88 B |
51.69%
|
Dec 31, 2019 | $0.58 B |
-4.30%
|
Dec 31, 2018 | $0.61 B |
-92.55%
|
Dec 29, 2017 | $8.17 B |
-53.78%
|
Dec 30, 2016 | $17.69 B |
-74.20%
|
Dec 31, 2015 | $68.54 B |
-45.64%
|
Dec 31, 2014 | $126.07 B |
117.05%
|
Dec 31, 2013 | $58.09 B |
17.30%
|
Dec 31, 2012 | $49.52 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Ionis Pharmaceuticals
IONS
|
$5.13 B |
-0.000 M
|
USA
|
Alnylam Pharmaceuticals
ALNY
|
$34.38 B |
-0.000 M
|
USA
|
Arrowhead Pharmaceuticals
ARWR
|
$2.45 B |
-0.000 M
|
USA
|
Sarepta Therapeutics
SRPT
|
$11.09 B |
0.000 M
|
USA
|
Moderna
MRNA
|
$14.82 B |
-0.000 M
|
USA
|
BioMarin Pharmaceutical
BMRN
|
$11.82 B |
0.000 M
|
USA
|
Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
Market Cap | = | RGLS Stock Price | * | RGLS Shares Outstanding |
= | $1.24 | * | 65.50 M | |
= | $81.22 M |